Enspryng (satralizumab-mwge) — Medica
Neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 antibody positive
Initial criteria
- age ≥ 18 years
- Diagnosis confirmed by a positive blood serum test for anti-aquaporin-4 antibody
- Medication prescribed by or in consultation with a neurologist
Reauthorization criteria
- age ≥ 18 years
- Diagnosis confirmed by a positive blood serum test for anti-aquaporin-4 antibody
- According to the prescriber, patient has had clinical benefit from the use of Enspryng (e.g., reduction in relapse rate, reduction in symptoms such as pain, fatigue, motor function, and a slowing in progression of symptoms)
- Medication prescribed by or in consultation with a neurologist
Approval duration
1 year